Home » Topics » BioWorld Science, Immune

BioWorld Science, Immune
RSS

Harbour BioMed completes phase I study of HBM-9161 in healthy Chinese subjects

Feb. 24, 2020

Privigen approved in Japan for agammaglobulinemia and hypogammaglobulinemia

Feb. 24, 2020

Mesoblast reports clinically meaningful outcomes for remestemcel-L in chronic GVHD

Feb. 21, 2020

New phase I trial evaluates safety and immunogenicity of dengusiil

Feb. 20, 2020

Progress in Human Cell Atlas unveiling underlying mechanisms of disease

Feb. 20, 2020

Merck KGaA presents PSMB8 inhibitors

Feb. 11, 2020

BiondVax reports preliminary phase II data on M-001 universal influenza vaccine candidate

Feb. 6, 2020

FDA approves Audenz to protect against influenza A (H5N1)

Feb. 4, 2020

FDA approves Palforzia oral immunotherapy for peanut allergy

Feb. 3, 2020

Kedrion Biopharma completes enrollment in phase III CARES10 study

Jan. 31, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...